Dupixent May Increase the Risk for Certain Lymphoma Cancers
You may be eligible for compensation
Dupixent (dupilumab) is an injectable biologic medication used to treat certain types of inflammatory diseases. It works by treating the underlying cause of inflammation and is commonly prescribed for people with atopic dermatitis, eczema, asthma, chronic sinusitis, and eosinophilic esophagitis.
Recent studies have shown that Dupixent use may increase the risk of certain types of cancers known as Cutaneous T-cell Lymphomas (CTCL), including its subtypes Mycosis fungoides and Sezary syndrome, by as much as 300% or more in people who used the medication. People who used Dupixent and were later diagnosed with CTCL may be eligible for compensation.
Dupixent Cutaneous T-cell Lymphoma Cancer Risk
As part of the immune system, skin plays a major role in the lymphatic system. Certain cancers of the lymph system are known as Lymphomas.
Cutaneous T-cell Lymphoma is a type of cancer that originates in the skin. It is one of the non-Hodgkins Lymphoma group of cancers that affects a certain type of white blood cell known as T-cells.
CTCL may include subtypes of Cutaneous T-cell Lymphoma including Sezary Syndrome, Mycosis Fungoides, and other T-cell Lymphoma subtypes.